Evidence map›Paper›PMID 42658634›Full record

ArticleCancer research communications2026

The GENIE Data Model: A Solid Tumor, Person-Centric Framework for Scalable, Harmonized Precision Oncology Data Collection.

Jennifer N Hoppe, Jocelyn Lee, Tomi F Akinyemiju, Danielle S Bitterman, Michael Brudno, Michelle F Green, Vojtech Huser, Jafi A Lipson, Sanjay Mishra, Daniel P Nussbaum and 9 more

Abstract read
In one paragraph

Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jennifer N HoppeAmerican Association for Cancer Research: Project GENIE, Philadelphia, Pennsylvania.ORCID 0009-0001-8987-4876
Jocelyn LeeBristol-Myers Squibb , Princeton, New Jersey.ORCID 0000-0002-6429-7478
Tomi F AkinyemijuDuke Cancer Institute, Duke University, Durham, North Carolina.ORCID 0000-0002-1412-3234
Danielle S BittermanAstraZeneca, Gaithersburg, Maryland.ORCID 0000-0003-0345-2232
Michael BrudnoGenetics and Genome Biology, SickKids Research Institute, Toronto, Canada.ORCID 0000-0001-7947-2243
Michelle F GreenLabcorp , Burlington, North Carolina.ORCID 0000-0002-6055-4342
Vojtech HuserEPAM, Cambridge, Massachusetts.ORCID 0000-0002-0709-6573
Jafi A LipsonStanford University School of Medicine, Stanford, California.ORCID 0000-0003-4671-5813
Sanjay MishraCenter for Clinical Cancer Informatics and Data Science, Legorreta Cancer Center, Brown University, Providence, Rhode Island.ORCID 0000-0002-7775-9600
Daniel P NussbaumDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0000-0003-3070-6605
Jai N PatelDivision of Cancer Pharmacology and Pharmacogenomics, Atrium Health Levine Cancer, Charlotte, North Carolina.ORCID 0000-0001-9845-3697
Valentina I PetkovSurveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.ORCID 0009-0009-8297-5381
Kelli M RasmussenAmerican Association for Cancer Research: Project GENIE, Philadelphia, Pennsylvania.ORCID 0000-0002-2946-9211
Sahussapont Joseph SirintrapunMass General Brigham , Boston, Massachusetts.ORCID 0000-0003-2921-8831
Patricia A SpearsThe University of North Carolina at Chapel Hill , Chapel Hill, North Carolina.ORCID 0000-0003-1167-0387
Sebastiaan Van SandijkEPAM, Cambridge, Massachusetts.ORCID 0000-0001-6557-3780
Anne-Marie Meyer *The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina.ORCID 0000-0003-4312-4727
Umit Topaloglu *Center for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, Maryland.ORCID 0000-0002-3241-8773
Jeremy L Warner *Center for Clinical Cancer Informatics and Data Science, Legorreta Cancer Center, Brown University, Providence, Rhode Island.ORCID 0000-0002-2851-7242

Funding

American Association for Cancer Research (AACR)
6 · The paper itself

Abstract

Adequately powered analyses in precision oncology often require combining cohorts across institutions. However, integration is constrained by the least granular source and may become infeasible when data elements are too heterogeneous to harmonize and map to a common data model. This challenge is acute in multi-institutional precision oncology research, in which real-world evidence requires harmonized clinico-omic data integration. Existing models often lack sufficient treatment patterns, outcomes, and genomic data, limiting interoperability and scalability. To address these gaps, American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (GENIE) developed the GENIE Data Model (GDM), a comprehensive, open-source oncology data model for scalable, consistent, and interoperable data collection across solid tumors, designed to effectively capture the journey of patients with cancer. Through iterative consensus-building, four working groups comprising 13 subject matter experts defined data elements across multiple clinical domains: patient characteristics, imaging, diagnosis, surgery, histopathology, biomarkers, systemic therapy, radiation, clinical trial history, disease response and outcomes, and social determinants of health. Elements were defined using standardized terminologies and permissible values to support mapping to Health Level 7 Fast Healthcare Interoperability Resources, Observational Medical Outcomes Partnership, and other existing oncology standards. The model architecture distinguishes manually abstracted elements from computationally collected elements, enabling parallel workflows. The GDM provides an extensible framework that addresses critical gaps and enables scalable, harmonized data collection essential for precision oncology and real-world evidence generation. SIGNIFICANCE: The GDM is an open-source, ready-to-implement, solid tumor framework that standardizes clinical and genomic data capture across institutions to effectively capture the journey of patients with cancer. It enables interoperable mapping to existing standards, accelerates multisite study start-up, and supports scalable real-world evidence generation in precision oncology.

Indexed as

Data CollectionMedical OncologyNeoplasmsPrecision MedicineGenomicsHumans

Identifiers

PMID42658634
PMCPMC13598700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.